4.5 Article

Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment

期刊

JAMA NEUROLOGY
卷 72, 期 12, 页码 1475-1483

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2015.2323

关键词

-

资金

  1. National Institutes of Health (NIH) [P50 AG16574, U01 AG06786, R01 AG11378]
  2. Elsie and Marvin Dekelboum Family Foundation
  3. Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation
  4. NIH
  5. NIH/National Institute on Aging (NIA)
  6. Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation
  7. NIH/NIA
  8. NIH (NIA and National Cancer Institute)
  9. Alzheimer Drug Discovery Foundation
  10. Lewy Body Dementia Association
  11. Michael J. Fox Foundation
  12. National Institute on Deafness and Other Communication Disorders
  13. Mangurian Foundation

向作者/读者索取更多资源

IMPORTANCE To understand how a model of Alzheimer disease pathophysiology based on beta-amyloidosis and neurodegeneration predicts the regional anatomic expansion of hypometabolism and atrophy in persons with mild cognitive impairment (MCI). OBJECTIVE To define the role of beta-amyloidosis and neurodegeneration in the subsequent progression of topographic cortical structural and metabolic changes in MCI. DESIGN, SETTING, AND PARTICIPANTS Longitudinal, observational study with serial brain imaging conducted from March 28, 2006, to January 6, 2015, using a population-based cohort. A total of 96 participants with MCI (all aged >70 years) with serial imaging biomarkers from the Mayo Clinic Study of Aging orMayo Alzheimer's Disease Research Center were included. Participants were characterized initially as having elevated or not elevated brain beta-amyloidosis (A+ or A-) based on C-11-Pittsburgh compound B positron emission tomography. They were further characterized initially by the presence or absence of neurodegeneration (N+ or N-), where the presence of neurodegeneration was defined by abnormally low hippocampal volume or hypometabolism in an Alzheimer disease-like pattern on (18)fluorodeoxyglucose (FDG)-positron emission tomography. MAIN OUTCOMES AND MEASURES Regional FDG standardized uptake value ratio (SUVR) and gray matter volumes in medial temporal, lateral temporal, lateral parietal, and medial parietal regions. RESULTS In the primary regions of interest (ROI), the A+N+ group (n = 45) had lower FDG SUVR at baseline compared with the A+ N-group (n = 17) (all 4 ROIs; P < .001). The A+ N+ group also had lower FDG SUVR at baseline (all 4 ROIs; P < .01) compared with the A-N-group (n = 12). The A+N+ group had lower medial temporal gray matter volume at baseline (P < .001) compared with either the A+ N-group or A-N-group. The A+ N+ group showed large longitudinal declines in FDG SUVR (P < .05 for medial temporal, lateral temporal, and medial parietal regions) and gray matter volumes (P < .05 for medial temporal and lateral temporal regions) compared with the A-N+ group (n = 22). The A+ N+ group also showed large longitudinal declines compared with the A-N- group on FDG SUVR (P < .05 for medial temporal and lateral parietal regions) and gray matter volumes (all 4 ROIs; P < .05) compared with the A+N-group. The A-N+group did not show declines in FDG SUVR or gray matter volume compared with the A+N-or A-N- groups. CONCLUSIONS AND RELEVANCE Persons with MCI who were A+N+ demonstrated volumetric and metabolic worsening in temporal and parietal association areas, consistent with the expectation that the MCI stage in the Alzheimer pathway heralds incipient isocortical involvement. The A-N+ group, those with suspected non-Alzheimer pathophysiology, lacked a distinctive longitudinal volumetric or metabolic profile.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据